Henagliflozin

Henagliflozin

Clinical data
Trade names	Rui Qin; 瑞沁
Other names	SHR3824; SHR-3824
Legal status
Legal status	Rx in China
Identifiers
IUPAC name (1R,2S,3S,4R,5R)-5-[4-Chloro-3-[(4-ethoxy-3-fluorophenyl)methyl]phenyl]-1-(hydroxymethyl)-6,8-dioxabicyclo[3.2.1]octane-2,3,4-triol
CAS Number	1623804-44-3
PubChem CID	56832738
DrugBank	DB11939
UNII	21P2M98388
Chemical and physical data
Formula	C22H24ClFO7
Molar mass	454.88 g·mol−1

Henagliflozin is a pharmaceutical drug for the treatment of type 2 diabetes. ^[1] In China, it is approved for adult patients with type 2 diabetes to improve the glycemic control. ^{[2] [3]}

Henagliflozin, like other drugs of the gliflozin class, inhibits the transporter protein sodium/glucose cotransporter 2 (SGLT2) which leads to a reduction in blood glucose levels. ^[4]

In a 26-week placebo-controlled trial of type 2 diabetics, telomere length significantly lengthened, the IGF-1 pathway was inhibited, and immune system function was improved in the henagliflozin group compared to the placebo group. ^[5]

References

1. Weng J, Zeng L, Zhang Y, Qu S, Wang X, Li P, et al. (August 2021). "Henagliflozin as add-on therapy to metformin in patients with type 2 diabetes inadequately controlled with metformin: A multicentre, randomized, double-blind, placebo-controlled, phase 3 trial". Diabetes, Obesity & Metabolism. 23 (8): 1754–1764. doi:10.1111/dom.14389. PMID   33769656.
2. Wang G (17 February 2022). "Monthly Report: New Drug Approvals in China, January 2022". BaiPharm. Henagliflozin Proline Tablets
3. "Henagliflozin - Jiangsu HengRui Medicine". AdisInsight. Springer Nature Switzerland AG.
4. He X, Liu G, Chen X, Wang Y, Liu R, Wang C, et al. (July 2023). "Pharmacokinetic and Pharmacodynamic Interactions Between Henagliflozin, a Novel Selective SGLT-2 Inhibitor, and Warfarin in Healthy Chinese Subjects". Clinical Therapeutics. 45 (7): 655–661. doi:10.1016/j.clinthera.2023.06.002. PMID   37451912.
5. Zhang J, Cai H, Xu J (2025). "Effect of henagliflozin on aging biomarkers in patients with type 2 diabetes: A multicenter, randomized, double-blind, placebo-controlled study". Cell Reports . 6 (9): 102331. doi:10.1016/j.xcrm.2025.102331. PMID   40912255.